ROCKWELL MEDICAL, INC. Form SC 13D/A November 13, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934 (Amendment No. 10)*

Rockwell Medical, Inc.

(Name of Issuer)

Common Shares, no par value per share

(Title of Class of Securities)

774374102

(CUSIP Number)

Robert L. Chioini

30142 Wixom Road

Wixom, Michigan 48393

(248) 960-9009

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 2, 2015

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

CUSIP No. 774374	102	13D				
1.	Name of Reporting Person Robert L. Chioini	on:				
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) o (b) o					
3.	SEC Use Only:					
4.	Source of Funds: PF					
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e): o					
6.	Citizenship or Place of Organization: United States of America					
Number of	7.	Sole Voting Power: 4,385,598				
Shares Beneficially Owned by	8.	Shared Voting Power: None				
Each Reporting Person With	9.	Sole Dispositive Power: 4,385,598				
	10.	Shared Dispositive Power: None				
11.	Aggregate Amount Beneficially Owned by Each Reporting Person: 4,385,598					
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): o					
13.	Percent of Class Represented by Amount in Row (11): 8.2%					
14.	Type of Reporting Person (See Instructions): IN					
		2				

CUSIP No. 774374102

13D

This Amendment No. 10 amends the Statement on Schedule 13D originally filed with the Securities and Exchange Commission on February 14, 2003 with respect to the common stock, no par value (the Common Shares), of Rockwell Medical, Inc. (Rockwell), as amended (the Schedule 13D). The Schedule 13D is further amended as set forth below. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Schedule 13D.

Item 5. Interest in Securities of the Issuer.

Item 5 is hereby amended by adding the following information:

(a) As of the date hereof, the Reporting Person beneficially owned 4,385,598 Common Shares (including 2,266,665 Common Shares issuable upon exercise of stock options held by the Reporting Person that are exercisable currently or within 60 days), constituting approximately 8.2% of the Common Shares outstanding, based on 51,077,877 Common Shares outstanding as of October 31, 2015.

The Reporting Person holds the following options to purchase Common Shares as of the date hereof:

Grant		# of	Exercise Price	# Vested Currently or Within 60	Verting Calcululati	Expiration
Date		Shares	Frice	Days	Vesting Schedule*	Date
	12/15/05	375,000	\$ 4.55	375,000	Fully Vested	12/15/2015
	12/17/07	250,000	\$ 6.50	250,000	Fully Vested	12/17/2017
	4/3/08	75,000	\$ 6.50	75,000	Fully Vested	4/3/2018
	11/19/08	175,000	\$ 3.09	175,000	Fully Vested	11/19/2018
	6/18/09	225,000	\$ 6.74	225,000	Fully Vested	6/18/2019
	1/15/10	150,000	\$ 7.13	150,000	Fully Vested	1/15/2020
	8/13/10	100,000	\$ 5.8618	100,000	Fully Vested	8/13/2020
	1/11/11	250,000	\$ 8.47	250,000	Fully Vested	1/11/2021
	1/05/12	225,000	\$ 10.04	225,000	Fully Vested	1/05/2022
	6/04/12	25,000	\$ 8.73	25,000	Fully Vested	6/04/2022
	1/31/13	250,000	\$ 6.12	166,666	One-third per year starting 1/31/14	1/31/2023
	1/13/14	250,000	\$ 10.10	83,333	One-third per year starting 1/13/15	1/13/2024
	10/1/14	250,000	\$ 8.88	83,333	One-third per year starting 10/1/15	10/1/2024
	10/1/14	250,000	\$ 8.88	83,333	One-third per year starting 10/1/15	10/1/2024
	10/2/15	500,000	\$ 8.23	0	One-third per year starting 10/2/16	10/2/2025
	10/2/15	250,000	\$ 8.23	0	One-third per year starting 10/2/16	10/2/2025

^{*}Option vesting accelerates upon death, disability or a change in control of Rockwell.

The Reporting Person currently holds 300,000 Common Shares that are part of unvested restricted stock grants that will vest as follows:

Grant Date	# of Shares	Vesting Date*	
10/2/2015	325,000	5/10/17	

^{*}Vesting accelerates upon death, disability or a change in control of Rockwell.

CUSIP No. 774374102

13D

(c) Other than the option and restricted stock grants described above, the Reporting Person has had the following transactions in the Common Shares since the filing of Amendment No. 9 to the Schedule 13D:

Date		# of Shares	Price	Transaction
	12/22/2014	335,000	\$ 2.79	Exercise stock option
	12/22/2014	260,000	\$ 8.56	Tender shares to company to pay exercise price & taxes
	3/2/2015	46,200	\$ 10.47	Tender shares to company to pay withholding taxes
	5/1/2015	73,200	\$ 9.64	Tender shares to company to pay withholding taxes
	8/13/2015	2,900	\$ 11.50	Market purchase
	8/13/2015	300	\$ 11.52	Market purchase
	8/13/2015	1,890	\$ 11.53	Market purchase
	8/14/2015	4,910	\$ 11.96	Market purchase

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Item 6 is hereby amended and restated in its entirety as follows:

The material terms of the options and restricted stock grants are set forth in Item 5 above. A total of 1,788,933 of the shares beneficially owned by the Reporting Person are held in a margin account with Morgan Stanley subject to a standard margin loan arrangement entered into on October 9, 2013.

Item 7. Material to be Filed as Exhibits.

Item 7 is hereby amended by adding the following information:

Amendment to October 1, 2014 Stock Option Agreement with Robert L. Chioini, filed as an exhibit to Rockwell s Annual Report on Form 10-K for the period ended December 31, 2014.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 13, 2015 /s/ Robert L. Chioini Robert L. Chioini

4